8-K: HeartSciences Expands Equity Incentive Plan, Grants Key Executive Awards, and Progresses Capital Raise

HeartSciences Inc. announced an increase in its equity incentive plan shares to 1,000,000, granted significant restricted stock units and stock options to executive officers and directors, and reported progress on its $15 million Regulation A offering and a debt-to-equity exchange.

Summary

• The Board of Directors approved Amendment No. 2 to the 2023 Equity Incentive Plan, increasing the maximum aggregate number of shares of common stock issuable under the Plan to 1,000,000 shares.
• The Plan Shares Increase Amendment will be considered and voted upon by the company's shareholders at the next annual meeting.
• The Compensation Committee amended existing cash bonus payment criteria and granted restricted stock unit (RSU) awards to executive officers.
• Andrew Simpson, Chief Executive Officer, received 68,750 RSUs, and Mark Hilz, Chief Operating Officer, received 56,250 RSUs.
• RSUs vest immediately upon the earlier of FDA clearance of the MyoVista Device (including AI algorithm) or the MyoVista Insights platform with the first AI algorithm, or upon a Change of Control.
• The Compensation Committee approved stock option awards to executive officers: Andrew Simpson (275,000 Options), Mark Hilz (225,000 Options), and Danielle Watson (25,000 Options).
• These options have an exercise price of $4.37 per share and will vest over three years, with one-third vesting on July 9, 2026, and the remaining two-thirds vesting in eight equal quarterly installments thereafter.
• Vesting of these options would accelerate upon the earlier of FDA clearance of the MyoVista Device/Insights platform or a Change of Control.
• Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells each received 25,000 stock options with an exercise price of $4.37 per share, with one-fourth vesting on October 9, 2025, and the remainder in three equal quarterly installments.
• As of July 11, 2025, the company has received $1.7 million in gross proceeds from its Regulation A Offering, resulting in the issuance of 487,701 Units, out of a maximum offering of $15,000,000 for 4,285,714 Units at $3.50 per Unit.
• Each Unit in the Regulation A Offering consists of one share of Series D Preferred Stock and one warrant to purchase one common share at an exercise price of $5.00 per share.
• As of July 11, 2025, holders of 229,665 shares of Series D Preferred Stock from the issued Units have elected to convert them into 229,665 shares of common stock.
• As of July 11, 2025, the company exchanged $855,000 of an unsecured promissory note for 233,229 shares of common stock.
• As a result of the Regulation A Issuance and the Debt Exchange, there are 1,555,049 shares of common stock issued and outstanding as of July 11, 2025.

Sentiment

Score: 6

Explanation: The document indicates positive steps in corporate governance by expanding the equity incentive plan and aligning executive compensation with key product milestones (FDA clearance). The ongoing capital raise and debt-to-equity exchange are also positive for financial health and operational flexibility, despite the capital raise being relatively small so far. The potential for dilution from new share issuances is a minor negative, but overall, the actions support future growth and stability.

Positives

• The increase in the equity incentive plan shares to 1,000,000 provides a larger pool for attracting and retaining talent.
• Granting of RSUs and stock options to key executives and directors aligns their compensation directly with critical company milestones, particularly FDA clearance of the MyoVista Device/Insights platform.
• The company has successfully raised $1.7 million in gross proceeds through its ongoing Regulation A Offering, contributing to capital resources.
• The debt-to-equity exchange of $855,000 reduces the company's outstanding debt, improving its financial structure.

Negatives

• The increase in the equity incentive plan shares and the issuance of new shares for the Regulation A offering and debt exchange could lead to dilution for existing shareholders.
• The Regulation A Offering has only raised $1.7 million out of a maximum target of $15 million, indicating that the full capital raise target has not yet been achieved.

Risks

• Vesting of significant executive and director equity awards (RSUs and Options) is contingent on FDA clearance of the MyoVista Device (including AI algorithm) or the MyoVista Insights platform with the first AI algorithm, introducing regulatory approval risk.
• The company's ability to raise the full $15,000,000 from the Regulation A Offering is not guaranteed, as only $1.7 million has been raised to date.

Future Outlook

The company anticipates a shareholder vote on the increased equity incentive plan shares at the next annual meeting. A key future milestone for executive and director equity award vesting is FDA clearance of the MyoVista Device (including AI algorithm) or the MyoVista Insights platform with the first AI algorithm. The Regulation A Offering is ongoing, aiming for a maximum of $15 million.

Management Comments

• The Plan Shares Increase Amendment shall be considered and voted upon the shareholders of the Company at the Company’s next annual meeting of shareholders.

Industry Context

The company operates in the medical device and AI diagnostics sector, specifically with its MyoVista Device and MyoVista Insights platform. The emphasis on FDA clearance for product commercialization and as a vesting trigger for executive compensation highlights the significant regulatory hurdles and market entry requirements typical for medical technology companies. The use of equity incentives tied to product milestones is a common strategy in this industry to align management with critical development and regulatory achievements.

Comparison to Industry Standards

• The granting of performance-based equity awards, particularly those tied to regulatory milestones like FDA clearance, is a standard practice in the medical device and biotech industries. This aligns executive incentives directly with critical product development and commercialization achievements, similar to companies like Edwards Lifesciences or Medtronic which often tie executive bonuses to product approvals or market launches.
• The use of a Regulation A offering for capital raising is common for smaller public companies or those transitioning from private to public, allowing them to raise capital from both accredited and non-accredited investors, similar to how some emerging biotech firms or health tech startups might fund their early growth stages.
• The debt-to-equity exchange is a common financial maneuver used by companies to reduce debt burden and improve balance sheet health, often seen in companies seeking to optimize their capital structure, comparable to actions taken by companies like Sorrento Therapeutics in managing their debt obligations.
• The increase in the equity incentive pool to 1,000,000 shares, while potentially dilutive, is a necessary step for a growing company to attract and retain talent, especially in competitive sectors like medical AI, where talent acquisition is crucial. This is a common practice across various industries, including tech and healthcare, to ensure competitive compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from the increased equity incentive plan shares, Regulation A offering, and debt-to-equity exchange. However, the alignment of executive incentives with FDA clearance could benefit long-term shareholder value. The debt reduction is positive for financial stability.
• Employees/Management/Directors: Significant new equity awards (RSUs and Options) provide strong incentives and compensation, particularly tied to key product development milestones.
• Creditors: The debt exchange reduces the company's outstanding unsecured promissory note, which is positive for creditors holding other forms of debt.
• Customers: No direct impact mentioned, but successful FDA clearance and product development (MyoVista Device/Insights) would ultimately benefit future customers.

Next Steps

• Shareholders will vote on the Plan Shares Increase Amendment at the next annual meeting.
• Continued efforts to achieve FDA clearance for the MyoVista Device (including AI algorithm) or the MyoVista Insights platform with the first AI algorithm, which will trigger vesting of significant executive and director equity awards.
• Ongoing efforts to raise capital through the Regulation A Offering.

Key Dates

Keywords

HeartSciences Inc., SEC Filing, 8-K, Equity Incentive Plan, Stock Options, Restricted Stock Units, Regulation A Offering, Debt Exchange, MyoVista Device, FDA Clearance, Corporate Governance, Executive Compensation, Share Dilution, Capital Raise